Drug price negotiations on the horizon

World of DTC Marketing

SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time.

Drugs 157

Drug pricing increases are disgraceful

World of DTC Marketing

SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices

Drugs 165
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

New cancer drug clinical trials struggling

World of DTC Marketing

This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.

Roche stops giving Huntington's disease drug in closely watched study

Bio Pharma Dive

A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals

DNA 250

Social media and prescription drugs: A study

World of DTC Marketing

QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study.

Drugs 165

Prescription drug marketing misconceptions

World of DTC Marketing

Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com.

Merck gives an early peek at COVID-19 drug results

Bio Pharma Dive

Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear

Drugs 238

Relay buys AI startup to aid unorthodox drug discovery quest

Bio Pharma Dive

The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year

Drugs 173

A startup raises $336M to make a better antibody drug for COVID-19

Bio Pharma Dive

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests

A closely watched schizophrenia drug fails key test

Bio Pharma Dive

Though a mid-stage study read out negative, Neurocrine still sees a path forward for the drug, which it licensed from Takeda last summer

A biotech shelves its Huntington's drugs after trial failures

Bio Pharma Dive

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis

Launching a drug in a pandemic

World of DTC Marketing

QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science.

Drugs 130

Lilly says diabetes shot outperformed rival Novo drug in study

Bio Pharma Dive

The results are a boost for Lilly's drug, tirzepatide, which is being prepared for regulatory submissions later this year. But long-term heart data won't be available for some time

Drugs 229

FDA grants approval to Ebola drug from Ridgeback

Bio Pharma Dive

In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb

Trials 232

FDA approves first-of-its-kind lupus drug

Bio Pharma Dive

Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year

Amgen study data bolster prospects of KRAS-blocking cancer drug

Bio Pharma Dive

Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings

Drugs 221

Acadia, with drug application rejected, calls out FDA for backtracking

Bio Pharma Dive

According to Acadia, the FDA took issue with the main study used in its drug approval submission. That surprised the company, since regulators had never seemed concerned with the study's design

Alnylam wins US approval for its third rare disease drug

Bio Pharma Dive

The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price

Drugs 227

8 amlodipine alternative drugs for blood pressure

Druggist

Amlodipine is one of the most commonly prescribed drugs in the UK and the most prescribed high blood pressure ( BP ) medication. When patients are diagnosed with high blood pressure and a drug is recommended, amlodipine may be the first choice, but not always.

Drugs 63

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

Lilly asks FDA to revoke clearance of first COVID-19 antibody drug

Bio Pharma Dive

The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug

Biogen stocks up on Sage's brain drugs in $3B deal

Bio Pharma Dive

By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor

Drugs 237

Valisure Supports Drug Importation

Pharmacy Checkers

online pharmacy that actually tests the quality of medication it sends to patients and apparently, to my delight, they support drug importation as a policy to lower costs. Food and Drug Administration to make sure those drugs will work as directed by their prescribers.

Biogen's all-important Alzheimer's drug enters the review gauntlet

Bio Pharma Dive

Meanwhile, the drug has also caught the attention of a powerful cost watchdog group On Nov. 6, aducanumab will go before a panel of experts who will review it and make recommendations to the FDA.

Drugs 272

Gilead's Veklury becomes first FDA-approved drug for COVID-19

Bio Pharma Dive

New results from an WHO study, however, raise questions about the drug's ultimate effectiveness The U.S. regulator granted a full approval after allowing emergency use earlier this year.

How to Lower Drug Prices

NY Times

Biologic drugs rack up billions in annual U.S. Drugs (Pharmaceuticals) Biotechnology and Bioengineering Humira (Drug) Prices (Fares, Fees and Rates) Law and Legislation Inventions and Patents Generic Brands and Productssales. Here’s a solution to lower the costs.

Sales 54

AstraZeneca cancer drug found ineffective for treating COVID-19

Bio Pharma Dive

The setback follows disappointing results from companies like Novartis and Sanofi, which have also sought to repurpose existing drugs for COVID-19

Drugs 229

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround

Can Amazon.com sell prescription drugs?

World of DTC Marketing

The news this week that Amazon.com is getting into the prescription drug business sent stocks of retail pharmacies down but questions sell remain. This week, Amazon’s news that they are finally leaping into the prescription drug business was not a shock.

Lilly gene-targeted drug shows potential for use across cancers

Bio Pharma Dive

Study results presented at AACR showed Retevmo shrank tumors in nine different cancers, building a case for the type of tissue-agnostic label that only three other medicines have secured

Gene 228

Gilead wins full approval for drug acquired in Immunomedics deal

Bio Pharma Dive

Trodelvy, a key drug for Gilead's ambitions in oncology, is now fully approved to treat an aggressive, hard-to-treat form of breast cancer

Drugs 134

Nitrous Nation: A Party Drug Endures

NY Times

A casual party drug endures. Drug Abuse and Traffic Drugs (Pharmaceuticals) Hsieh, Tony Addiction (Psychology) WhippetsHippie crack. Whippets. Laughing gas.

Drugs 62

Biogen laser-focused on Alzheimer's drug as rest of business falters

Bio Pharma Dive

While the biotech prepares to launch aducanumab, its latest earnings report shows significant hits to top-selling drugs, plus another pipeline failure

Drugs 237

Vir shares tumble after apparent setback for COVID-19 drug

Bio Pharma Dive

The NIH stopped enrolling patients hospitalized with coronavirus disease into a study of Vir's antibody drug after data monitors questioned its effectiveness

Drug side effects should be easier to understand

World of DTC Marketing

SUMMARY: Per the Times, “what if consumers could calculate the benefits and risks of taking a prescription drug as easily as they can gauge the carbohydrates and calories in an Oreo cookie?” ” Drug facts boxes are needed, but the FDA disagrees. A Drug Facts Box?

Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others

Bio Pharma Dive

A large safety study found that patients given Pfizer's Xeljanz had health issues like major heart complications and cancer at a higher rate than those who got a different kind of anti-inflammation drug

Drugs 263

AbbVie, Biogen lead pharma in new year's drug price hikes

Bio Pharma Dive

Average list price increases across the drug industry, however, appear lower than last year, according to one analysis

Drugs 173

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

AC Immune drug fails in blow to another Alzheimer's hypothesis

Bio Pharma Dive

Negative results for the experimental drug semorinemab dents a theory that Alzheimer's disease may be caused by tangles of the protein tau in the brain

Merck, in latest COVID-19 setback, scraps one drug and pins hopes on another

Bio Pharma Dive

The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines

Amgen acquires a small biotech and its inflammatory disease drug

Bio Pharma Dive

The deal for Rodeo Therapeutics follows closely on the heels of the large biotech's buyout of cancer drug developer Five Prime

FDA advisers reassert case against approval of Biogen's Alzheimer's drug

Bio Pharma Dive

In a new editorial, three of the agency's advisers reiterated that they see "no persuasive evidence to support approval of aducanumab at this time "

Drugs 233

The top drugs that could be impacted by an obscure provision in the pandemic relief law

Bio Pharma Dive

Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs